Core Insights - The article emphasizes the importance of long-term wealth creation through value growth investing, value investing, and dividend investing [1] - The author expresses a commitment to writing articles focused on fundamental value investing, aiming to identify great companies at fair prices [1] Group 1 - The author has over 7 years of investing experience, primarily focusing on long-term strategies [1] - The educational background of the author is in Biology, specifically molecular cell biology, which informs their analytical approach to investing [1] - The articles will be based on personal experience, research, and literature related to building long-term wealth [1] Group 2 - The author has a beneficial long position in HALO shares, indicating a personal investment interest [2] - The article reflects the author's opinions and is not influenced by compensation from any company mentioned [2] - There is no business relationship with any company whose stock is discussed in the article [2]

European Commission (EC) decision on marketing authorization application expected within approximately two monthsSAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human ...

Complaint filed in New Jersey alleges Merck uses Halozyme's patented MDASE technology to develop SC Keytruda Halozyme is seeking damages and injunctive relief to stop the infringement SAN DIEGO, April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. (Merck) in U.S. District Court in New Jersey. Halozym ...

Core Insights - Halozyme Therapeutics, Inc. announced that argenx received FDA approval for VYVGART® Hytrulo prefilled syringe for self-injection, targeting adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [1][2] Group 1: Product Details - VYVGART® Hytrulo is designed for a 20-to-30-second subcutaneous injection, allowing self-administration by patients or caregivers after proper training [2] - The approval is based on studies demonstrating bioequivalence to the vial version of VYVGART® and successful administration by participants in human factors validation studies [2] Group 2: Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences through its ENHANZE® drug delivery technology, which facilitates rapid subcutaneous delivery of biologics [3] - The company has impacted over one million patients globally through its technology, which is licensed to major pharmaceutical companies including Roche, Takeda, and Pfizer [3] Group 3: Additional Products and Technologies - Halozyme also develops drug-device combination products using advanced auto-injector technologies aimed at enhancing patient comfort and adherence [4] - The company has two proprietary commercial products, Hylenex® and XYOSTED®, and is engaged in ongoing development with partners like Teva Pharmaceuticals [4]

Subcutaneous DARZALEX® is co-formulated with Halozyme's ENHANZE® drug delivery technologySAN DIEGO, April 9, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval for an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) co-formulated with ENHANZE® in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidom ...

Core Points - Halozyme Therapeutics announced the European Commission's marketing authorization for the subcutaneous formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for first-line treatment of advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations [1] - The approval also includes amivantamab as a monotherapy for advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy [1] - The subcutaneous formulation utilizes Halozyme's ENHANZE® drug delivery technology, which aims to improve patient experience by reducing administration time and infusion-related reactions [2][3] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes, particularly through its ENHANZE® drug delivery technology [4] - The company has successfully licensed its ENHANZE® technology to major pharmaceutical companies, impacting over one million patients globally [4] - Halozyme also develops drug-device combination products aimed at improving convenience, reliability, and patient adherence [5]

A decision on the European marketing authorization extension for the subcutaneous formulation of Opdivo is expected by June 2, 2025 About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluid ...

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as recommendations or advice for any financial actions [1]. - The content is not tailored to individual financial situations or needs, highlighting the necessity for users to perform their own assessments [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - Users are encouraged to understand these instruments fully before engaging in any trading activities [1]. - The website does not provide real-time information and may not guarantee the accuracy of the data presented [1].

Halozyme Therapeutics (HALO) reported fourth-quarter 2024 adjusted earnings of $1.26 per share, which beat the Zacks Consensus Estimate of $1.16. The company had recorded adjusted earnings of 82 cents per share in the year-ago period.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues in the fourth quarter increased 30% year over year to $298 million. Revenues surpassed the Zacks Consensus Estimate of $284 million.The top-line growth was primarily driven by higher royalty paym ...

Halozyme Therapeutics (HALO) Q4 2024 Earnings Call February 19, 2025 12:51 AM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate CommunicationHelen Torley - President & Chief Executive OfficerNicole LaBrosse - CFOMichael Difiore - Managing DirectorJason Butler - Managing Director & Biotechnology Equity Research Conference Call Participants Sean Laaman - AnalystBrendan Smith - Director - Senior AnalystMohit Bansal - AnalystJessica Fye - Managing Director & Equity Research Analy ...